Journal article

Use of Folic Acid-Containing Supplements after a Diagnosis of Colorectal Cancer in the Colon Cancer Family Registry

Rebecca S Holmes, Yingye Zheng, John A Baron, Lin Li, Gail McKeown-Eyssen, Polly A Newcomb, Mariana C Stern, Robert W Haile, William M Grady, John D Potter, Loic Le Marchand, Peter T Campbell, Jane C Figueiredo, Paul J Limburg, Mark A Jenkins, John L Hopper, Cornelia M Ulrich

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION | AMER ASSOC CANCER RESEARCH | Published : 2010

Abstract

BACKGROUND: Supplement use among cancer patients is high, and folic acid intake in particular may adversely affect the progression of colorectal cancer. Few studies have evaluated the use of folic acid-containing supplements (FAS) and its predictors in colorectal cancer patients. OBJECTIVE: To assess the use of FAS, change in use, and its predictors after colorectal cancer diagnosis. DESIGN: We used logistic regression models to investigate predictors of FAS use and its initiation after colorectal cancer diagnosis in 1,092 patients recruited through the Colon Cancer Family Registry. RESULTS: The prevalence of FAS use was 35.4% before and 55.1% after colorectal cancer diagnosis (P = 0.004). W..

View full abstract

Grants

Awarded by NIH


Awarded by National Cancer Institute, NIH


Awarded by NATIONAL CANCER INSTITUTE


Awarded by NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES


Funding Acknowledgements

NIH grants: R01C105437, R25CA94880 and 5T32DK007742. This work was supported by the National Cancer Institute, NIH under RFA # CA-95-011 and through cooperative agreements with members of the C-CFR and Principal Investigators.